Azo chemistry and its potential for colonic delivery

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 23, Issue 5, 2006, Pages 349-399

  Jain, Anekant ^a   Gupta, Yashwant ^a   Jain, Sanjay K ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Azo conjugates; Azo aromatic polymer; Biodegradable polymers; Colon delivery; Redox hydrogels; Redox mediators

Indexed keywords

ALOSETRON; ANTIBIOTIC AGENT; AZATHIOPRINE; AZO COMPOUND; AZO REDUCTASE; BALSALAZINE; BUDESONIDE; CIMETROPIUM; COTRIMOXAZOLE; DICYCLOVERINE; DRUG CARRIER; FLUOROURACIL; HYDROCORTISONE; INFLIXIMAB; INSULIN; IPSALAZINE; MEBEVERINE; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; OLSALAZINE; POLYMER; PREDNISOLONE; PRODRUG; PROPANTHELINE BROMIDE; SALAZOSULFAPYRIDINE; SCOPOLAMINE; TEGASEROD; TRIMEBUTINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BIODEGRADABILITY; CHEMOTHERAPY; COLITIS; COLON; COLON CROHN DISEASE; COLON DISEASE; COLON DIVERTICULOSIS; COLORECTAL CANCER; CROSS LINKING; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TARGETING; ENTERITIS; GASTROINTESTINAL ABSORPTION; HIRSCHSPRUNG DISEASE; HUMAN; HYDROGEL; HYDROPHILICITY; HYDROPHOBICITY; INTESTINE FLORA; NONHUMAN; OXIDATION REDUCTION REACTION; PH; POLYMERIZATION; REVIEW; STRUCTURE ACTIVITY RELATION; SYMPTOM; ULCERATIVE COLITIS; UPPER GASTROINTESTINAL TRACT;

EID: 34047183018     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevtherdrugcarriersyst.v23.i5.10     Document Type: Review

References (132)

1. Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv Drug Del Rev. 2005;57:267-79.
2. Ardizzone S. Drugs used in ulcerative colitis. Orphanet encyclopedia 2003. (September): http://www.orpha.net/data/patho/GB/UC-drugs.pdf
3. Reddy MS, Sinha RV, Reddy DS. Novel oral colon-specific drug delivery systems for pharmacotherapy of peptide and non-peptide drugs. Drugs Today. 1999;35(7):537.
4. Belknap WM. Hirschsprung's Disease. Curr Treat Options Gastroenter. 2003;6:247-56.
5. Haupt S, Rubinstein A. The colon as a possible target for orally administered peptide and protein drugs. Crit Rev Therap Drug Carr Syst. 2002;19(6):499-551.
6. Rubinstein A. Colonic drug delivery. Drug Discov Today: Technol. 2005;2(1):33-7.
7. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharmaceut Sci. 2003;6:33-66.
8. Longer MA, Woodley JF, Duncan R. Comparison of the activities of rat small intestine and colon brush border membrane peptidases. Proc Int Symp Contrl Rel Bioact Mater. 1989;16:225-6.
9. MacFarlane GT, Cummings JH, MacFarlane S, Gibson GR. Influence of retention time on degradation of pancreatic enzymes by colonic bacteria grown in 3-stage continuous culture system. J Appl Bacteriol. 1989;67:521-7.
10. Taniguchi K, Muranishi S, Sezaki H. Enhanced intestinal permeability to macromolecules II. Improvement of the large intestinal absorption of heparin by lipid-surfactant mixed micelles in rat. Int J Phar. 1980;4:219-28.
11. Scheline RR. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol Rev. 1973;25(4):452-523.
12. Friend DR. New oral delivery systems for treatment of inflammatory bowel disease. Adv Drug Deliv Rev. 2005;57:247-65.
13. Basit AW. Advances in colonic drug delivery. Drugs. 2005;65:1991-2007.
14. Kosaraju SL. Colon targeted delivery systems: review of polysaccharides for encapsulation and delivery Crit Rev Food Sci Nut. 2005;45:251-8.
15. Vandamme ThF, Lenourry A, Charrueau C, Chaumeil J-C. The use of polysaccharides to target drugs to the colon. Carbohyd Polymers. 2002;48(3):219-31.
16. Sinha VR, Kumria R. Polysaccharides in colon-specific drug delivery. Int J Pharm. 2001;224:19-38.
17. Hawksworth G, Drasar BS, Hill MJ. Intestinal bacteria and hydrolysis of glycosidic bonds. J Med Microbiol. 1971;4:451-9.
18. Scheline RR. Toxicological implications of drug metabolism by intestinal flora. Eur Soc Study Drug Tox Proc. 1972;13:35-43.
19. Walker R. The metabolism of azo compounds: a review of the literature. Fd Cosmet Toxicol. 1970;8:659-76.
20. Mitsuoka T. Intestinal bacteria and health. Tokyo: Harcourt Brace Javanovich, 1978.
21. Brown JP. Reduction of polymeric azo and nitro dyes by intestinal bacteria. Appl Environ Microbiol. 1981;41:1283-6.
22. Renwick AG. First pass metabolism within the lumen of the gastrointestinal tract. In: George CF, Shand G, Renwick AG, editors. Clinical pharmacology and therapeutics Vol. I Presystemic drug elimination. London: Butterworth Scientific; 1982.
23. Scheline RR, Nygaard RT, Longberg B. Enzymatic reduction of the azo dye acid yellow by extracts of Streptococcus faecalis isolated from rat intestine. Food Cosmet Toxicol. 1970;8:55-8.
24. Soleim H, Scheline RR. Metabolism of xenobiotics by strains of intestinal bacteria. Acta Pharmacol Toxicol. 1972;31:471-80.
25. Roxon JJ, Ryan AJ, Wright SE. Enzymatic reduction of tartrazine by Proteus vulgaris from rats. Food Cosmet Toxicol. 1967;5:645-56.
26. Murrels DF. The reduction of food azo dyes by rat caecal microflora with particular reference to Streptococcus faecalis. Ph.D. Thesis. University of Reading 1969.
27. Gingell R, Walker R. Mechanisms of azo-reduction by Streptococcus faecalis. II. The role of soluble flavins. Xenobiotica. 1971;1:231-9.
28. Walker R, Gingell R. An assay for azo-reductase activity in microorganisms. Biochem J. 1971;122:18P.
29. Walker R, Gingell R, Murrells D. Mechanisms of azo reduction by Streptocococcus facaelis optimization of assay conditions. Xenobiotics. 1971;1:221-9.
30. Kopecek J, Kopeckova P. N-(2-hydroxypropyl)methacrylamide copolymers for colon-specific drug delivery. In: Friend DR, editor. Oral colon-specific drug delivery. London: CRC Press; 1992.
31. Brondsted H. Hydrogels for colon specific peptide delivery. Ph.D. Thesis. 1991. University of Utah, Salt Lake City, UT.
32. Gingell R. Substrate non-specificity of Streptococcus faecalis azoreductase. Xenobiotica. 1973;3:165-9.
33. Walker R, Ryan AJ. Some molecular parameters influencing rate of reduction of azo compounds by intestinal microflora. Xenobiotica. 1971;1:483-6.
34. Bragger J. The design of drug delivery systems for the colon [PhD Thesis]. London: Kings College London, University of London; 1995.
35. Brewster D. Drug metabolism by gastrointestinal microorganisms characteristics and biological implications. Rev Drug Metab Drug Interact. 1981;3:227-53.
36. Larsen JC, Meyer T, Scheline RR. Reduction of sulphonated water-soluble azo dyes by caecal microorganisms from the rat. Acta Pharmacol Tox. 1976;38:353-7.
37. Scheline RR. Toxicological implications of drug metabolism by intestinal flora. Eur Soc Study Drug Tox Proc. 1972;13:35-43.
38. Saffran M, Kumar GS, Savariar C, Burnham JC, Williams F, Neckers DC. A new approach to the oral administration of insulin and other peptide drugs. Science. 1986;33:1081-4.
39. Saffran M, Bedra C, Kumar GS, Neckers DC. Vasopressin: a model for the study of effects of additives on the oral and rectal administration of peptide drugs. J Pharm Sci. 1988;77:33-8.
40. Saffran M, Field JB, Pena J, Jones RH, Okuda Y. Oral insulin in diabetic dogs. J Endocrinol. 1991;131:267-78.
41. Baranov VG, Belovintseva MF, Schukovskaya LL, Kropachev VL, Shvartz SI. Saccharolytic action of some insulin polymer derivatives in eternal administration to animals. Probl Endokrinol Mosk. 1975;21:88.
42. Saffran M, Kumar GS, Neckers DC, Pena J, Jones RH, Field JB. Biodegradable azopolymer coating for oral delivery of peptide drugs. Biochem Soc Trans. 1990;18:752.
43. Miller JA, Baumann CA. The carcinogenicity of certain azo dyes related to p-dimethylaminoazobenzene. Cancer Res. 1945;5:227.
44. Cook JW, Hewett CL, Kennaway EL, Kennaway NM. Effects produced in the livers of mice by azonapthalenes and related compounds. Am J Cancer. 1940;40:62.
45. Sisley P, Porscher C. Du sort des matieres colorants dans l'organisme animal. C. R. hebd. Seanc Acad Sci Paris. 1911;152:1062.
46. Fuller AT. Is p-aminobenzenesulphonamide the active agent in prontosil therapy? Lancet. 1937;1:194.
47. Mueller GC, Miller JA. The metabolism of 4-dimethylaminoazobenzene by rat liver homogenates. J Biol Chem. 1948;176:535.
48. Mueller GC, Miller JA. The reductive cleavage of 4-imethylaminoazobenzene by rat liver. The intracellular distribution of the enzyme system and its requirement for triphosphopyridine nuleotide. J Biol Chem. 1949;180:1125.
49. Mueller GC, Miller JA. The reductive cleavage of 4-imethylaminoazobenzene by rat liver. Reactivation of carbon dioxide treated homogenates by riboflavin-adenine dinucleotide. J Biol Chem. 1950;185:145.
50. Manchon PH, Lowy R. Etudes sur l'activite azoreductasique des surnageants d'homogenat de foie de rat. II. Comparaison avec d'autres preparations. Variations avec l'age et l'ingestion de colorant. Fd Cosmet Toxicol. 1965;3:775.
51. Fouta JR, Kamm JJ, Brodie BB. Enzymatic reduction of prontosil and other azo dyes. J Pharmac Exp Ther. 1957;120:291.
52. Mason RP, Peterson FJ, Holtzman JL. Inhibition of azoreductases by oxygen. The role of the azo anion free radical metabolite in the reduction of oxygen to superoxide. Mol Pharmacol. 1978;14:665-71.
53. Renton KW. Methyl red azo-reductase and its induction by 3-methylcholanthrene in the liver of different species. Xenobiotica. 1980;10:243-6.
54. Domagk G. Ein Beilrag zur Chemotherapie der bakteriellen Infektionen. Dtsch. Med Wochellschr. 1935;61:250.
55. Domagk G. Eine neue Klasse von Desinfektionsmitteln Dtsch. Med Wochenscrh. 1935b;61:829.
56. Trefouel J, Nittti F, Bovet D. Activite du p-aminophenylsulfamide sur les infections streptococciques. Expermentales de la souris et du lapin. C.r. Seanc Soc Biol. 1935;120:756.
57. 14C-5-aminosalicylic acid. Acta Med Scand. 1963;173:61.
58. 35S-sulfapyridine. Acta Med Scand. 1963;173:391.
59. Gingell R, Bridges JW, Williams RT. The role of the gut flora in the metabolism of prontosil and neoprontosil in the rat. Xenobiotica. 1971;1:143.
60. Gingell R, Bridges JW. Intestinal azo-reduction and glucuronide conjugation of prontosil. Xenobiotica. 1973;3:599.
61. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972;181:555.
62. Goldman P. Drug metabolism by gastrointestinal flora. Three case histories. In: Prescott LF, Nimmo WS, editors. Drug absorption. Proceedings of the International Conference on Drug Absorption. New York: Edinburgh ADIS Press; 1980.
63. Schroder H, Gustafsson BE. Azo reduction of salicylazosulfapyridine in germ free and conventional rats. Xenobiotica. 1973;3:225.
64. Schroder H, Johansson AK. Redox potential in caecal contents of the rat and azo reduction of salicyl-azo-sulphapyridine. Xenobiotica. 1973;3:233.
65. Campieri M, Lanfranchi GA, Bazzocchi G, Brignola C, Sarti F, Franzin G, Battoccia A, Labo G, Dal Monte PR. Treatment of ulcerative colitis with high dose 5-aminosalicylic acid enemas. Lancet. 1981;2:270.
66. Khan Azad AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulfasalazine. Lancet. 1977;2:892.
67. Khan Azad AK, Guthrie G, Johnston HH, Truelove SC, Williamson DH. Tissue and bacterial splitting of sulphasalazine. Clin Sci. 1983;64:349.
68. Chung KT, Fulk GE, Egan M. Reduction of azo dyes by intestinal anaerobes. Appl Environ Microbiol. 1978;35:558.
69. Dubin P, Wright KL. Reduction of azo food dyes in cultures of Proteus vulgaris. Xenobiotica. 1975;5:563-71.
70. Brown JP, McGarrough GV, Parkinson TM, Wingerd RE Jr., Onderdonk AB. Polymeric drug for treatment of inflammatory bowl disease. J Med Chem. 1983;26:1300-7.
71. Hartman CP, Fulk GE, Andrews AW. Azo reduction of trypan blue to a known carcinogen by a cell-free extract of a human intestinal anaerobe. Mutat Res. 1978;58:125.
72. Broders AC, Bargen JA. Salicylazosulfadimethyl-pyrimidine (azudimidine) in treatment of chronic ulcerative colitis. Writings and Reports corrected. Scott and White Clinic.1962;3:229.
73. Baron JH, Connell AM, Lennard-Jones JE, Avery Jones F. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet. 1962;2:1094.
74. Goligher JC de Domba, T Watts J, Watkinson G. Medical treatment in ulcerative colitis. Baltimore, MD: Balier Tindall and Cassell, 1968.
75. Ireland A, Mason CH, Jewell DP. Controlled trial comparing olsalazine and sulfasalazine for maintenance treatment of ulcerative colitis. Gut. 1988;29:835.
76. Meyers S, Sachar DB, Present DH, Janowitz HD. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective randomized placebo-controlled double blind dose-ranging clinical trial. Gastroenterology. 1987;93:1255.
77. Sandberg-Gertzen H, Jarnerot G, Kraaz W. Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. Gastroenterology. 1986;90:1024.
78. Sandberg-Gertzen H, Jarnerot G, Tysk C. Long-term treatment with olsalazine for ulcerative colitis safety and relapse-prevention a follow-up studies. Scand J Gastroenterol. 1988;23(148):48.
79. Peppas NA, Mikos AG. Preparation methods and structure of hydrogels. In: Peppas NA, editor. Hydrogels in medicine and pharmacy. Vol. 1. Boca Raton (FL): CRC Press; 1986.
80. Peppas NA. Preparation and characterization of cross-linked hydrophilic networks. In: Brannon-Peppas L, Harland RS, editors. Absorbent olymer echnology. Amsterdam: Elsevier; 1990.
81. Grahan NB, McNeil ME. Hydrogels for controlled drug delivery. Biomaterials. 1984;5:27-36.
82. Bae YH, Kim SW. Hydrogels delivery systems based on polymer blends block-copolymers or interpenetrating networks. Adv Drug Del Rev. 1993;11:109-35.
83. Flory PJ, Rehner J. Statistical mechanics of cross-linked polymer networks. II. Swelling. J Chem Phys. 1943;11:521-6.
84. Flory PJ. Statistical mechanics of swelling of network structures. J Chem Phys. 1950;18:108-11.
85. Flory PJ. Principles of polymer chemistry. Ithaca (NY): Cornell University Press; 1953.
86. Ratner BD, Hoffman AS. Synthetic hydrogels for biomedical applications. In: Andrade JD, editor. Hydrogels for medical and related applications. ACS Symposium Series No. 31. Washington, D.C.: American Chemical Society; 1976.
87. Peppas NA. Hydrogels in medicine. Boca Raton (FL): CRC Press; 1986.
88. Peppas NA, Langer R. New challenges in biomaterials. Science. 1994;263:1715-20.
89. Brondsted H, Kopecek J. Hydrogels for site-specific oral drug delivery. Synthesis and characterization. Biomaterials. 1991;12:584-92.
90. Brondsted H, Kopecek J. Hydrogels for site-specific drug delivery to the colon in vitro and in vivo degradation. Pharm Res. 1992;9:1540-5.
91. Yin Y, Yang Y, Xu H. Hydrogels for colon-specific drug delivery. Swelling kinetics and mechanism of degradation in vitro. J Polymer Sci Part B Polymer Physics. 2001;39:3128-37.
92. Yin Y, Yang Y, Xu H. Hydrophobically modified hydrogels containing azoaromatic cross-links swelling properties degradation in vivo and application in drug delivery. Euro Polymer J. 2002;38:2305-11.
93. Kopecek J, Kopeckova P, Brondsted H, Rathi R, Rihova B, Yeh PY, Ikesue K. Polymers for colon-specific drug delivery. J Controlled Release. 1992;19:121-30.
94. Yeh PY, Kopeckova P, Kopecek J. Biodegradable and pH-sensitive hydrogels. Synthesis by cross-linking of N,N-dimethacrylamide copolymer precursors. J Polym Sci. 1994;32:1627-37.
95. Yeh PY, Berenson MM, Samowitz WS, Kopeckova P, Kopecek J. Site-specific drug delivery and penetration enhancement in the gastrointestinal tract. J Controlled Release. 1995;36:109-24.
96. Ghandehari H, Kopeckova P, Kopecek J. In vitro degradation of pH sensitive hydrogels containing aromatic azo bonds. Biomaterials. 1997;18:861-72.
97. Shanta KL, Ravichandran P, Rao KP. Azo polymeric hydrogels for colon targeted drug delivery. Biomaterials. 1995;16:1313-8.
98. Akala EO, Kopeckova P, Kopecek J. Novel pH-sensitive hydrogels with adjustable swelling kinetics. Biomaterials. 1998;19:1037-47.
99. Ulbrich K, Subr V, Podperova P, Buresva M. Synthesis of novel hydrolytically degradable hydrogels for controlled drug release. J Controlled Release. 1995;34:155-65.
100. Ulbrich K, Subr V, Seymour LW, Duncan R. Novel biodegradable hydrogels prepared using divinylic cross-linking agent NO-dimethacryloylhydroxylamine. 1. Synthesis and characterization of rates of gel degradation and rate of release of model drugs in vitro and in vivo. J Controlled Release. 1993;24:181-90.
101. Yeh PY, Kopeckova P, Kopecek J. Degradability of hydrogels containing azoaromatic cross-links. Macromol Chem Phys. 1995;196:2183-202.
102. Brondsted H, Kopecek J. pH-sensitive hydrogels characteristics and potential in drug delivery. In: Harland R, Prudhomme R, editors. Polyelectrolyte gels. ACS Symposium Series No. 480. Washington (DC): American Chemical Society; 1992.
103. Maris BL, Verheyden K, Van Reeth C, Samyn P, Augustijns R, Kinget G, Van den Mooter G. Synthesis and characterization of inulin-azo hydrogels designed for colon targeting. Int J Pharm. 2001;213:143-52.
104. Kakoulides EP, Smart JD, Tsibouklis J. Azocrosslinked poly(acrylic acid) for colonic delivery and adhesion specificity synthesis and characterization. J Controlled Release. 1998;52:291-300.
105. Soozandehfar SH, Bragger JL, Martin GP, Lloyd AW. Synthesis and bacterial degradation of an azopolymer. Int J Pharm. 2000;198:71-82.
106. Schacht E, Wilding IR. Process for the preparation of azo- and/or disulfide-containing polymers. 1991. PCT (Patent Cooperation Treaty) WO91/11175.
107. Cheng CL, Gehrke SH, Ritschel WA. Development of an azo polymer based colonic release capsule for delivering proteins/macromolecules. Meth Find Exp Clin Pharmacol. 1994;16:271-8.
108. Van den Mooter G, Samyn C, Kinget R. Azo polymers for colon-specific drug delivery. Int J Pharm. 1992;87:37-46.
109. Van den Mooter G, Samyn C, Kinget R. Azo polymers for colon-specific drug delivery. II Influence of the type of azo polymer on the degradation by intestinal microflora. Int J Pharm. 1993;97:133-9.
110. Van den Mooter G, Samyn C, Kinget R. The relation between swelling properties and enzymatic degradation of azo polymers designed for colon-specific drug delivery. Pharm Res. 1994;11:1737-41.
111. Van den Mooter G, Samyn C, Kinget. R. Characterization of colon-specific azo polymers: A study of the swelling properties and the permeability of isolated polymer films. Int J Pharm. 1994;11:127-36.
112. Van den Mooter G, Samyn C, Kinget R. In vivo evaluation of a colon-specific drug delivery system. An absorption study of theophylline from capsules coated with azopolymers in rats. Pharm Res. 1995;12:244-7.
113. Van den Mooter G, Offringa M, Kalala W, Samyn C, Kinget R. Synthesis and evaluation of new linear azo polymers for colonic targeting. S. T. P. Pharma Sci. 1995;5:36-40.
114. Samyn C, Kalala W, Van den Mooter G, Kinget R. Synthesis and in vitro biodegradation of poly(ether-ester) azo polymers designed for colon targeting. Int J Pharm. 1995;121:211-6.
115. Kalala W, Kinget R, Van den Mooter G, Samyn C. Colonic drug targeting. In vitro release of ibuprofen from capsules coated with poly(ether-ester) azo polymers. Int J Pharm. 1996;139:187-95.
116. Schacht E, Gevaert A, Kenawy ER, Molly K, Verstraete W, Adriaensens P, Carleer R, Gelan J. Polymers for colon specific drug delivery. J Controlled Release. 1996;39:327-38.
117. Ueda T, Yamaoka T, Miyamoto M, Kimura Y, Sasatani H, Kim SI. Bacterial reduction of azo compounds as a model reaction for the degradation of azo-containing polyurethane by the action of intestinal flora. Bull Chem Soc Jpn. 1996;69:1139-42.
118. Yamaoka T, Makita Y, Sasatani H, Kim S, Kimura Y. Linear type azo-containing polyurethane as drug-coating material for colon-specific delivery. Its properties, degradation, behavior and utilization for drug formulation. J Controlled Release. 2000;66:187-97.
119. Kimura Y, Makita Y, Kumagai T, Yamane H, Kitao T, Sasatani H, Kim SI. Degradation of azo-containing polyurethane by the action of intestinal flora. Its mechanism and application as a drug delivery system. Polymer. 1992;33:5294-9.
120. Chavan MS, Sant VP, Nagarsenker MS. Azo containing urethane analogues for colonic drug delivery synthesis. Characterization and in-vitro evaluation. J Pharm Pharmacol. 2001;53:895-900.
121. Mirelman D, Izhar M, Eshdat Y. Carbohydrate recognition mechanisms which mediate microbial adherence to mammalian mucosal surfaces. Tokai J Exp Clin Med. 1982;7 Suppl:177-83.
122. Kopecekova P, Rathi R, Takada S, Rihova B, Berenson MM, Kopecek J. Bioadhesive N-(2-hydroxypropyl) methacrylamide copolymers for colon-specific drug delivery. J Controlled Release. 1994;28:211-22.
123. Kopeckova P, Kopecek J. Release of 5-aminosalicylic acid from bioadhesive N-(2-hydroxypropyl)methacrylamide copolymers by azoreductases in vitro. Makromol Chem. 1990;191:2037-45.
124. Gingell R, Walker R. Mechanism of azo reduction by non-specificity of Streptococcus faecalis azo reductase. Xenobiotica. 1975;5:563-71.
125. Stirrup V, Evans DF, Ledingham S, Thomas M, Pye G, Hardcastle J.D. Redox potential measurement in the gastrointestinal tract in man. In: Garner A, O'Brien PE, editors. Proceedings of the World Congress on Gastroenterology and Digestive Endoscopy; 1990 August 30; Sydney, Australia. John Wiley.
126. Bragger JL, Lloyd AW, Soozandehfar SH, Bloomfield SF, Marriott C, Martin GP. Investigations into the azo reducing activity of a common colonic microorganism. Int J Pharm. 1997;157:61-71.
127. Larsel GL, Larson JP, Gustafsson JA. Cystein conjugate beta-lyase in the gastrointestinal bacterium Fusobacterium necrophorum. Xenobiotica. 1983;13:687-93.
128. Kimura Y, Kim S, Nishiura A. Polyurethanes. European Patent. EP 0398472, 1991.
129. Van Hees PA, van Eferen L, Margry R, van Rossum JM, van Tongeren JH. Factors that may influence the effect of salazopyrin in the management of Crohns Disease. Wetermanl, T, Pena AS, Booth. CE, editors. Proceedings of the Workshop on Crohn's Disease; 1975 Oct 25; Leyden, The Netherlands. Amsterdam: Excerpta Medica; 1976. .
130. Houston JB, Day J, Walker J. Azo reduction of sulphasa1azine in healthy volunteers. Br J Clin Pharmacol. 1982;14:395.
131. Chung KT, Stevens SE Jr, Cerniglia CE. The reduction of azo dyes by the intestinal microflora. Crit Rev Microbiol. 1992;18:175-90.
132. Chung KT, Cerniglia CE. Mutagenicity of azo dyes structure-activity relationships. Mut Res. 1992;277:201-20.